We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.75%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
(+2.2%)
Cap. Flow
-$18.8M
Cap. Flow
% of AUM
-0.51%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$134M |
| 2 |
Eli Lilly
LLY
|
+$114M |
| 3 |
Hologic
HOLX
|
+$80.8M |
| 4 |
NeoGenomics
NEO
|
+$60.6M |
| 5 |
Biogen
BIIB
|
+$55.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$182M |
| 2 |
Intuitive Surgical
ISRG
|
+$103M |
| 3 |
AbbVie
ABBV
|
+$66.8M |
| 4 |
Medtronic
MDT
|
+$61.4M |
| 5 |
Bausch Health
BHC
|
+$60M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.32% |
| 2 | Technology | 1.61% |
| 3 | Financials | 0.8% |
| 4 | Consumer Discretionary | 0.14% |
| 5 | Miscellaneous | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
SentinelOne
S
$7.51B
| $8.5M | 0.23% |
+200,000
| New | +$8.5M |
2021 Q2
0 quarters
|
|
77
DELISTED
Esperion Therapeutics
ESPR
| $8.46M | 0.23% |
+400,000
| New | +$9.63M |
2021 Q2
0 quarters
|
|
|
ONCS
78
DELISTED
OncoSec Medical Incorporated
ONCS
| $7.87M | 0.21% |
127,273
-30,454
| -19% | -$2.76M |
2020 Q4
2 quarters
|
|
79
Instil Bio
TIL
$40.1M
| $7.73M | 0.21% |
20,000
| – | – |
2021 Q1
1 quarter
|
|
80
Vir Biotechnology
VIR
$1.69B
| $7.66M | 0.21% |
+162,000
| New | +$7.37M |
2021 Q2
0 quarters
|
|
81
Pharvaris
PHVS
$1.95B
| $7.45M | 0.2% |
400,000
| – | – |
2021 Q1
1 quarter
|
|
82
GeneDx Holdings
WGS
$1.9B
| $7.36M | 0.2% |
15,909
-758
| -5% | -$325K |
2021 Q1
1 quarter
|
|
83
Monte Rosa Therapeutics
GLUE
$831M
| $6.81M | 0.18% |
+300,000
| New | +$6.11M |
2021 Q2
0 quarters
|
|
84
Denali Therapeutics
DNLI
$2.81B
| $6.75M | 0.18% |
+86,100
| New | +$5.33M |
2021 Q2
0 quarters
|
|
85
DELISTED
AtaiBeckley Inc
ATAI
| $6.49M | 0.18% |
+350,987
| New | +$6.48M |
2021 Q2
0 quarters
|
|
86
DELISTED
Tourmaline Bio
TRML
| $6.41M | 0.17% |
+43,636
| New | +$6.68M |
2021 Q2
0 quarters
|
|
87
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $5.36M | 0.14% |
500,000
| – | – |
2021 Q1
1 quarter
|
|
|
BLSA
88
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $5.26M | 0.14% |
500,000
| – | – |
2020 Q4
2 quarters
|
|
|
MSAC
89
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $5.02M | 0.14% |
+520,000
| New | +$5.08M |
2021 Q2
0 quarters
|
|
90
FIGS
FIGS
$3.18B
| $5.01M | 0.14% |
+100,000
| New | +$3.74M |
2021 Q2
0 quarters
|
|
|
PANA
91
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| $5.01M | 0.14% |
+500,000
| New | +$5.01M |
2021 Q2
0 quarters
|
|
92
Senti Biosciences Holdings
SNTI
$7M
| $4.97M | 0.13% |
+50,000
| New | +$4.99M |
2021 Q2
0 quarters
|
|
|
HCAQ
93
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
| $4.92M | 0.13% |
500,000
| – | – |
2021 Q1
1 quarter
|
|
94
Celcuity
CELC
$2.77B
| $4.8M | 0.13% |
+200,000
| New | +$5.15M |
2021 Q2
0 quarters
|
|
95
DELISTED
Confluent
CFLT
| $4.75M | 0.13% |
+100,000
| New | +$4.84M |
2021 Q2
0 quarters
|
|
|
CMIIU
96
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
| $4.44M | 0.12% |
330,000
-6,700
| -2% | -$89.2K |
2021 Q1
1 quarter
|
|
97
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $4.39M | 0.12% |
+150,000
| New | +$4.45M |
2021 Q2
0 quarters
|
|
98
MoonLake Immunotherapeutics
MLTX
$813M
| $4.14M | 0.11% |
400,000
| – | – |
2020 Q4
2 quarters
|
|
99
Orchestra BioMed
OBIO
$328M
| $4.08M | 0.11% |
400,000
| – | – |
2020 Q3
3 quarters
|
|
|
SNCE
100
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $4M | 0.11% |
20,000
| – | – |
2020 Q4
2 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2021 Portfolio in Review
As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
- Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
- Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
- Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
- Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
- Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
- Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
- Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.
Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.